scholarly journals Aberrantp16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer

2003 ◽  
Vol 106 (6) ◽  
pp. 913-918 ◽  
Author(s):  
Sonata Jarmalaite ◽  
Annamaria Kannio ◽  
Sisko Anttila ◽  
Juozas R. Lazutka ◽  
Kirsti Husgafvel-Pursiainen
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Promoter Methylation ◽  
Nonsmall Cell Lung Cancer ◽  
Former Smokers

RETRACTED ARTICLE: Promoter methylation of DAPK gene may contribute to the pathogenesis of nonsmall cell lung cancer: a meta-analysis

Tumor Biology ◽  
2014 ◽  
Vol 35 (6) ◽  
pp. 6011-6020 ◽  
Author(s):  
Fan-Fan Li ◽  
Yang Yang ◽  
Xiao-Lei Wang ◽  
Yan-Yan Hong ◽  
Nian-Fei Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Promoter Methylation ◽  
Meta Analysis ◽  
Nonsmall Cell Lung Cancer ◽  
Retracted Article

Promoter methylation of the RGC32 gene in nonsmall cell lung cancer

Cancer ◽  
2010 ◽  
Vol 117 (3) ◽  
pp. 590-596 ◽  
Author(s):  
Dong Sun Kim ◽  
Ji Yun Lee ◽  
Su Man Lee ◽  
Jin Eun Choi ◽  
Sukki Cho ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Promoter Methylation ◽  
Nonsmall Cell Lung Cancer

scholarly journals Retraction Note to: Promoter methylation of DAPK gene may contribute to the pathogenesis of nonsmall cell lung cancer: a meta-analysis

Tumor Biology ◽  
2015 ◽  
Vol 36 (9) ◽  
pp. 7303-7303
Author(s):  
Fan-Fan Li ◽  
Yang Yang ◽  
Xiao-Lei Wang ◽  
Yan-Yan Hong ◽  
Nian-Fei Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Promoter Methylation ◽  
Meta Analysis ◽  
Nonsmall Cell Lung Cancer

scholarly journals Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy

2021 ◽  
Vol 9 (3) ◽  
pp. e002262
Author(s):  
Justin Ferdinandus ◽  
Martin Metzenmacher ◽  
Lukas Kessler ◽  
Lale Umutlu ◽  
Clemens Aigner ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Metabolic Response ◽  
Standard Of Care ◽  
Nonsmall Cell Lung Cancer ◽  
Published Data ◽  
Complete Metabolic Response ◽  
Positron Emission ◽  
Checkpoint Inhibitor Therapy

IntroductionImmunotherapy is the new standard of care in advanced nonsmall cell lung cancer (NSCLC). Recently published data show that treatment discontinuation after 12 months of nivolumab treatment is associated with shorter survival. Therefore, the ideal duration of immunotherapy remains unclear, and finding markers of beneficial outcomes is of great importance. Here, we determine the proportion of complete metabolic responses (CMR) in patients who have not progressed after 24 months of immunotherapy.MethodsThis is a retrospective analysis of 45 patients with positron emission tomography using 2-[18F]fluoro-2-deoxy-D-glucose imaging for assessment of residual metabolic activity after at least 24 months. CMR was defined as uptake in tumor lesions below background levels, using mediastinum as a reference. ResultsOut of 45 patients, 29 patients had a CMR (64%). CMR was observed more frequently in non-first-line patients. Patients with CMR were younger (median 65.7 vs 75.5, p=0.03). Fourteen patients with CMR have discontinued therapy and have not progressed until time of analysis; however, median follow-up was only 5.6 (range 0.8–17.0) months.ConclusionAfter a minimum of 24 months of palliative immunotherapy for NSCLC, CMR occurred in almost two thirds of patients. Potentially, achievement of CMR might identify patients, for whom palliative immunotherapy may be safely discontinued.

Sign in / Sign up

Export Citation Format

Share Document